1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legal & IP

$3M Verdict Against Cook In IVC Filter Case

 
• By Elizabeth Orr

An Indianapolis federal jury has awarded $3m to a woman who says a Cook intravenous filter broke apart within her body. This is the the third bellwether case in ongoing multi-district litigation, and the first that has ruled against Cook.

Gavel
• Source: Shutterstock

The third in a series of bellwether cases involving Cook Medical Inc.’s inferior vena cava (IVC) filters ended in a partial victory for the plaintiff on Feb. 5, as an Indianapolis federal jury awarded $3m in compensatory damages to a woman who says she was injured by the product.

However, the jury rejected a request for punitive damages and for further compensatory damages.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

Whistleblower Suit Against UnitedHealth Continues After Semler, Bard Settle Related Cases

 
• By Elizabeth Orr

Insurance firm UnitedHealth is facing allegations the company intentionally used an unreliable PAD screening method to increase its reimbursements under Medicare Advantage. Semler Scientific and Bard, which respectively made and manufactured the products in question, settled related cases for $37m.

FTC’s New Healthcare Division Chief Is Former Antitrust Prosecutor

 
• By Malcolm Spicer

Emma Mittelstaedt Burnham prosecuted antitrust violations in healthcare sector in her previous work at DoJ, including leading investigation into antitrust cartels in the generic pharmaceutical industry.

FCA Enforcement Shows No Signs of Slowing, Attorney Tells Medtech Companies

 
• By Elizabeth Orr

Federal False Claims Act settlements hit $3.8bn in the first half of fiscal 2025, with enforcement expected to intensify, Barnes & Thornburg partner Jackie Papish tells Medtech Insight. Key watch areas include qui tam cases, DEI policy implications, and growing scrutiny of diagnostics.

Oura Gets Competitors Banned From US Market, But Faces Ultrahuman Countersuit

 
• By Elizabeth Orr

The US International Trade Commission has banned smart rings from Ultrahuman and RingConn after Oura Health's patent infringement case. Ultrahuman countersued, claiming Oura infringes its intellectual property. Sales and marketing of the affected rings will cease on October 22.

More from Policy & Regulation

Biolinq Aims To ‘Shine’ In Early 2026 With Needle-Free CGM US Debut, Human Data On Protein Sensor

 
• By Marion Webb

Fresh off de novo clearance, Biolinq plans to launch its needle-free CGM for type 2 diabetes not on insulin in early 2026. Pricing has not been disclosed, but “won’t be too far apart” over rivals Abbott’s Lingo and Dexcom’s Stelo CGMs, CEO Rich Yang said.

Blood Volume, Reimagined: Daxor’s BVA Could Slash Testing Time and Save Lives

 
• By Elizabeth Orr

The Daxor Blood Volume Analysis (BVA) is aimed at improving care for heart failure patients. It will allow blood volume to be measured from the patient’s bedside for the first time and is also significantly faster than earlier testing methods.

FDA Wants Help In Figuring Out How AI-Enabled Devices Work In ‘The Real World’

 
• By Brian Bossetta

The US FDA is seeking public input on practical approaches to evaluating the performance of AI-enabled medical devices. The agency says it wants to build off insights gained from a public advisory committee last year that discussed how best to evaluate these devices once they are in use.